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Background: In 2001 Liou published a 5-year survival model using CFF Registry data.
Aims: To evaluate its validity in predicting survival in Italian CF patients.
Methods: In a retrospective study on 945 patients, the 9 variables selected by Liou were analyzed, vital status on December 2008 recorded and
observed and expected deaths compared. To develop a new model, patients were randomly divided into a derivation (n=475) and a validation
sample (n=470).
Results: A signiﬁcant difference was found between observed and expected deaths based on Liou's model (62 vs 94), with a 34% reduction in
mortality (pb0.05). A new model (based on FEV1, Staphylococcus aureus and Burkholderia cepacia complex infection, number of pulmo-
nary exacerbations/year) was generated, that correctly predicted survival in the validation sample (31 observed vs 29 expected deaths,
p=0.660).
Conclusions: The Liou model did not adequately predict 5-year survival in our CF population that, compared to the one in which it was originally
tested, could beneﬁt from 10 years of improvement in treatments and practice patterns. A new generated model, based on only four variables, was
more accurate in predicting 5-year survival in Italian CF patients.
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Multivariate statistical models that estimate the risk of poor
survival in cystic fibrosis (CF) patients may assist in clinical
practice, particularly in the selection of the most appropriate
candidates for lung transplantation.
For the latter purpose, for many years clinicians used a sur-
vival model developed in 1992 that was based on forced expi-
ratory volume in 1 s (FEV1) alone (1). Several years later (in
2001) Liou et al. described a 5-year survivorship model created
and validated on 1993 Cystic Fibrosis Foundation Patient Reg-
istry data (2). A wide spectrum of clinical variables was tested
by univariate logistic regression analyses, of which 21 were
found to be significantly predictive of 5-year survivorship.
These variables were included in a multivariate logistic model
that identified 9 characteristics of the disease that together
could accurately predict survival (age, FEV 1%, gender,
weight-for-age z-score, pancreatic sufficiency, diabetes melli-
tus, Staphylococcus aureus infection, Burkholderia cepacia
complex infection and number of acute pulmonary exacerba-
tions per year).
The model was proposed as a rigorous tool for clinical prac-
tice and research, and also as a method for estimating the im-
pact of new therapies or practice patterns and their possible
survival effect. However, over the last decade there were few
reports on the application of this model on other CF popula-
tions (3–6) and no attempts were made to track its validity
over time.
Our primary aim was therefore to evaluate the validity of the
Liou model to predict 5-year survival of CF patients in regular
follow-up at Italian CF Centers over the period from 2003 to
2008. The secondary objective was to generate a new model
based on the data of the same CF population.
2. Methods
A multicenter retrospective cohort study was carried out
within the Italian Society for CF (SIFC). Patients born before
January 1, 1999, who were alive and older than 5 years on De-
cember 31, 2003, and for whom follow-up data were available
through December 31, 2008, were included. Vital status (alive
or dead) was recorded at the end of 2008, and the variables
identified as survival predictors by Liou et al. were collected
(age, gender, FEV1, exocrine pancreatic function, diabetes, S.
aureus and B. cepacia complex infection and the number of
acute pulmonary exacerbation per year). Patients were excluded
from the study if they had undergone solid organ transplanta-
tion before or during the study period, or if they lacked any
of the covariates of interest. FEV1 was expressed as percentage
of the predicted value for age (7), weight-for age z-score was
calculated according to CDC standards (8,9).
Clinical status was defined as follows: patients were defined
as pancreatic sufficient if they did not require pancreatic en-
zyme supplementation with meals; diabetes was defined by
the need for insulin treatment during or before 2003; S. aureus
and B. cepacia complex infection by the presence of at least
one positive culture during the year 2003; the number ofacute exacerbations was the number of episodes of acute pul-
monary exacerbation that occurred during the year 2003 requir-
ing antibiotic therapy by any way of administration.
Five-year survival was the outcome variable and death for
any cause was considered.
Informed consent was previously obtained for collection and
use of clinical data for the Italian CF Registry.
2.1. Statistical analysis
In order to test the hypothesis that the Liou model can cor-
rectly predict 5-year survival in our Italian CF patient popula-
tion, the Chi-square test was employed to compare observed
and expected deaths. The number of expected survivors was
calculated as the sum of individual probability of survival be-
yond 5 years.
A new multiple logistic regression was then performed, con-
sidering as dependent variable the survival after 5 years and as
independent variables, those included in the Liou model.
After testing the “full model”, we looked for the best model
using backward selection.
We then assessed the ability of the different survival models
to classify correctly vital status after 5 years; for this purpose,
the areas under the Receiver Operator Characteristic Curve
(ROC AUC) were calculated.
Diagnostic accuracy of the survival models and FEV1 alone
was evaluated. Sensitivity, Specificity, Positive Predictive
Value (PPV) and Negative Predictive Value (NPV), positive
and negative Likelihood Ratio (+LR and −LR) were calculated
by comparing the observed vital status outcomes of patients
with those predicted from the models based on different cut-
off points for the probability of survival. Similar calculations
were performed for various FEV1 cut-off points.
In addition, for the internal validation of the new model, pa-
tients were randomly divided into two groups, a derivation
sample (n=475) and a validation sample (n=470). Based on
the mortality rate over the period of interest, we used the deri-
vation sample to develop the survival predictive model, that
was then tested on the validation sample to evaluate its efficacy.
We estimated an expected mortality rate of 6% over the 5-
year period, a figure that was derived from the Italian CF Reg-
istry data (10). A total number of 700 patients was considered
necessary to detect, with an α error of 0.05, a difference greater
than 30% between expected and observed mortality (mortality
rate lower than 4.2% or higher than 7.8%).
3. Results
Nine Italian CF Centers participated in the study and provided
data for 1029 patients meeting the inclusion criteria and represent-
ing approximately 20% of the Italian CF population. Eighty-four
patients with incomplete data were excluded from statistical anal-
ysis, that was therefore performed on 945 patients. Quality of data
was checked centrally by RB, and Centers were asked to report
missing or incomplete data.
Table 1 shows demographic and clinical characteristics of
our CF population in comparison to that considered by Liou
Table 1
Demographic and clinical characteristic of patients examined in the present
study in comparison with the population of Liou's study (1).
Present study Liou's study
N. of patients 945 a 5820 b
Age (years)
Mean (SD) 18.49 (9.65) 17.58 (9.25)
Median (range) 16.42 (5–62) 15.52 (5–62)
Female gender 48% 47%
FEV1 (% of predicted value)
Mean (SD) 82 (27.24) 67.7 (29.2)
Median (25th–75th centile) 84 (63–102) –
Weight (z-score)
Mean (SD) −0.70 (1.13) −0.85 (1.07)
Median (25th–75th centile) −0.74 (−1.47 to +0.02) –
Pancreatic sufficiency 19% 5.3%
Diabetes 12.1% 6.1%
Staphylococcus aureus infection 60.4% 30.6%
Burkholderia cepacia complex
infection
9.4% 3.2%
Pulmonary exacerbation
Mean (range) 1.53 (0–14) 1.1 (0–18)
Median (25th–75th centile) 2 (1–3) –
a Including both the development and the validation patients.
b Including only the development patients.
Table 2
The new 5-year survivorship model for CF using the same clinical variables
proposed by Liou (1). Multiple logistic regression analysis.
β
coefﬁcient
p value Odds
ratio
Odds ratio
Lower
limit
(95%)
Upper
limit
(95%)
Intercept −1.2775 0.1071
Age (years) 0.0156 0.4167 1.0157 0.9782 1.0546
Female gender −0.2348 0.4745 0.7907 0.4154 1.5050
FEV1 0.0726 b0.0001 1.0753 1.0530 1.0980
Weight for age z-score 0.1195 0.4507 1.1270 0.8260 1.5376
Pancreatic sufficiency 0.9253 0.1762 2.5226 0.6600 9.6414
Diabetes −0.4936 0.1899 0.6104 0.2918 1.2769
Staphylococcus aureus 0.7132 0.0328 2.0405 1.0599 3.9286
Burkholderia cepacia
complex
−1.3900 0.0166 0.2491 0.0799 0.7768
Pulmonary exacerbation −0.2855 0.0004 0.7516 0.6412 0.8811
Exacerbation×Burkholderia
cepacia complex
0.1673 0.2935 1.1822 0.8651 1.6154
P-values less than 0.05 are shown in italics.
Table 3
Multiple logistic regression of 5-year survival including the 4 variables
significantly associated with 5-year survival in our sample).
β
coefﬁcient
p
value
Odds
ratio
Odds ratio
Lower limit
(95%)
Upper limit
(95%)
Intercept −1.2700 0.0121
FEV1 0.0722 b0.0001 1.0749 1.0561 1.0939
Staphylococcus
aureus
0.7124 0.0281 2.0388 1.0796 3.8502
Burkholderia
cepacia complex
−1.0997 0.0017 0.3330 0.1675 0.6621
Pulmonary
exacerbation
−0.2473 0.0003 0.7809 0.6827 0.8932
P-values less than 0.05 are shown in italics.
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differences included FEV1 values (that were substantially
lower in the American population), and pancreatic sufficiency
(almost four times more frequent in the Italian population); fre-
quencies of diabetes, S. aureus and B. cepacia complex infec-
tions and number of pulmonary exacerbations per year were
much higher among Italian compared to American patients.
A significant difference was found between the actual number
of deaths that occurred during the study period among Italian CF
patients and the number of deaths predicted by the survival model
proposed by Liou (expected deaths). Compared with the 94
deaths expected according to Liou's model (9.9% of the subjects
alive at the start of the study), we observed 62 deaths (6.6% of the
subjects alive at the start of the study), with a difference of −34%
(pb0.05).
The results of multiple logistic regression analysis, using the
variables included in the Liou model, are reported in Table 2.
Four of these variables (FEV1, S. aureus and B. cepacia com-
plex infection and number of pulmonary exacerbations) were
found to be significantly associated with 5-year survival.
In the “full model” (including all the variables selected by
Liou), the odds ratio of 5-year survival was 1.0753 for each
unit of FEV1, 2.0405 in case of S. aureus infection, 0.2491 in
case of B. cepacia complex infection and 0.7809 for each pul-
monary exacerbation during 2003. The area under the curve
(AUC) ROC was 0.935 (95% CI: 0.917–0.950).
Table 3 shows the results of multiple logistic regressions
obtained after backward selection for variables significantly
associated with survival.
In the “parsimonious model” (4 variables), the odds ratio of
5-year survival was 1.0749 for each unit of FEV1, 2.038 in case
of S. aureus infection, 0.333 in case of B. cepacia complex in-
fection and 0.7516 for each pulmonary exacerbation during
2003. The AUC ROC was 0.930 (95% CI: 0.912–0.945).A model based on the four above mentioned variables was
derived from half of our population (n=475) (derivation sam-
ple), that was very similar to the model derived from the
whole population (model not shown). In the validation sample
(n=470), this model was able to correctly predict the actual
number of deaths (31 observed vs 29 expected, p=0.66).
Table 4 shows the estimated odds ratios based on the “full
model” and the “parsimonious model”, in comparison to the
odds ratios obtained in the model derived on the whole sample
and in the Liou model. It should be noted that 7 of the 9 covari-
ates selected by Liou had odds ratios in the original paper that
fall within the 95% confidence limits reported in Table 2 of
the present study, and that only FEV1% (Liou's model odds
ratio 1.04, present study 95% CI 1.053–1.098) and acute pul-
monary exacerbations (Liou's model odds ratio 0.63, present
study 95% CI 0.6412–0.8811) did not fall within the 95% con-
fidence limits.
As shown in Table 5, the diagnostic accuracy of the “full
model”, of the “parsimonious model” and of FEV1 alone was
good and all were able to predict survival, as indicated by the
ROC AUC values (full model 0.935, 95% CI 0.917–0.950;
Table 4
Odds ratio derived from different model of survival.
Liou's
model
Our models
Full
model
Parsimonious
model
Age (years) 0.97 1.02
Gender (F) 0.79 0.79
FEV1 1.04 1.08 1.07
Weight for age z-score 1.50 1.13
Pancreatic sufficiency 1.58 2.52
Diabetes 0.61 0.61
Staphylococcus aureus 1.24 2.04 2.04
Burkholderia cepacia complex 0.16 0.25 0.33
Pulmonary exacerbation 0.63 0.75 0.78
Exacerbation×Burkholderia cepacia complex 1.49 1.18
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0.909, 95% CI 0.889–0.927).
Diagnostic characteristics of the two survival models at two
cut-off points of survival probability (95% and 50%) and of
FEV1 alone (at 30% and 60% of the predicted values) were
also evaluated. Setting as a positive result of the test a probabil-
ity of survival b95%, both models showed high sensitivity,
specificity and NPV, but a modest PPV. In contrast, setting as
a positive result of the test a probability of survival b50%,
the models showed high specificity but very low sensitivity,
indicating that a positive result of the test is more reliable
than a negative one (+LRN24, −LR=0.7).
Using FEV1 alone, a patient with FEV1 less than 60% showed
a high probability of survival (99%, −LR=0.2), whereas a patient
with FEV1 less than 30% showed a high probability of dying
within 5 years (50%, +LR=13.9).
4. Discussion
The development of a reliable and accurate prognostic indica-
tor of survival in CF is considered of major importance in clinical
practice to be used as an objective aid to individual patients and
their physicians contemplating difficult therapeutic choices. For
many years the most commonly used survival model was based
on FEV1 alone (1). Ten years ago, Liou et al. proposed a more
complex 5-year survivorship model that for the first time wasTable 5
Diagnostic accuracy of FEV1 and multiple logistic regression models for predicting
AUC ROC Cut-off value
Full model a 0.935 Probability of survival b50%
Probability of survival b95%
Parsimonious model b 0.930 Probability of survival b50%
Probability of survival b95%
FEV1 0.909 b30% of predicted
b60% of predicted
Abbreviation: AUC = area under the curve, PPV = positive predictive value, NPV =
LR (+; −) = likelihood ratio (positive; negative test).
a Variables included in the full model: age (years), gender, FEV1, weight for age
cepacia, pulmonary exacerbations, exacerbation×Burkholderia cepacia complex.
b Variables included in the parsimonious model: FEV1, Staphylococcus aureus, Bbased on several clinical characteristics of CF. This prognostic
model was shown to be more accurate, with potential to have
widespread application (2). Since then, the Liou model has
been employed mostly to select the appropriate patients for lung
transplantation (11), but no attempts were made to validate it in
a different CF population outside the US.
The primary objective of our study was to test the ability of
the Liou model to predict mortality within 5 years in a wide
sample of Italian CF patients. We therefore collected all the 9
variables considered by Liou in his original study (2).
Our population was composed of 945 CF patients in regular
follow-up at 9 Italian CF Reference Centers, and it was similar
to the whole Italian population according to the 2004 Italian
Registry data (4099 patients) with regard to mean age
(18 years) and gender distribution (48% females) (Table 1).
With regard to pancreatic status, the percentage of patients
with pancreatic sufficiency (19%) was also quite similar
(19.5%) to that found in a recent Italian multicenter study carried
out to evaluate growth patterns in 892 children with CF with a
mean age of 9.2 years (12).
Our population was comparable to that studied by Liou with
regard to age and gender distribution (Table 1), but clinically dif-
ferent and this may reflect at least in part differences in genetic
background.
Frequency of F508del mutation in Italy is lower (52% of CF
chromosomes) than that found in North American CF patients
(13) and this may account for the lower frequency of pancreatic
insufficiency in our patients (12).
The Italian population was also remarkably healthier with
regard to lung function and nutritional status, but more likely
to be affected by diabetes and infections with B. cepacia com-
plex and S. aureus, and to have acute exacerbations of CF. The
mortality was also substantially lower in Italian CF patients;
this finding may be mainly related to a birth cohort effect
(14–16) and only in part to genotype differences (17). It should
be noted that the data used by Liou to develop his model were
obtained in 1993, whereas we collected our data 10 years later.
Over this period of time, our ability to detect pulmonary ex-
acerbations and diabetes has greatly improved and treatment for
these complications has certainly become more aggressive.
This is particularly true in Italy, where a specific law put into
effect in 1993 gave CF patients followed in specialized CF5-year mortality.
Sensitivity Speciﬁcity +LR −LR PPV NPV
0.274 0.989 24.9 0.7 0.630 0.951
0.919 0.809 4.8 0.1 0.252 0.993
0.290 0.988 24.2 0.7 0.621 0.952
0.919 0.804 4.7 0.1 0.248 0.993
0.194 0.986 13.9 0.8 0.500 0.946
0.855 0.821 4.8 0.2 0.251 0.988
negative predictive value.
z-score, pancreatic sufﬁciency, diabetes, Staphylococcus aureus, Burkholderia
urkholderia cepacia complex, pulmonary exacerbations.
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CF care.
We could not confirm the ability of the Liou model to accu-
rately predict 5-year survival in our population. Indeed a sub-
stantial difference between expected and observed deaths was
documented, with a significant reduction in overall mortality
(−33%).
Median predicted survival varies from year-to-year in CF
registries (18), and temporal fluctuations in annual age-
specific mortality rates cannot be excluded (19). On the other
hand, the decrease in mortality over a period of 10 years is
not surprising. Over the past 20 years the median age of survival
in patients with CF has greatly increased both in US and in
Europe, including Italy (20–22,10).
An increasing number of therapeutic strategies have become
available that may slow the progression of pulmonary disease
(23). Specifically, two major changes in therapy have occurred
between 1993 and 2003: both recombinant human DNase and in-
haled tobramycin (24) were brand new and had little penetrance
in the US when the study by Liou et al. had taken place, whereas
in 2003, most eligible patients were actually using these medica-
tions in the US as well as in Italy.
In the most advanced stages of the disease, novel and more
aggressive therapeutic approaches (including non-invasive ven-
tilation techniques) (25), have permitted survival in relatively
stable conditions of extremely compromised patients who
would not have survived during the nineties.
CF survival has improved particularly in childhood, in the
2–15 year old group (26,27), however it is unlikely that the
lower number of deaths observed among Italian CF patients
can be attributed to younger age, since the age distribution in
the two populations was quite similar.
Improvement in survival may be one of the factors that could
explain the failure of the Lioumodel to correctly predict mortality
in the Italian population, since the impact of a few prognostic fac-
tors on survival may have changed over time. It has been shown
for example that CF-related diabetes (CFRD) has a major impact
on survival, with less than 25% of CF patients with CFRD reach-
ing the age of 30 years compared to about 60% of those without
CFRD (28). Longitudinal evaluation at one large CF Center has
documented steady improvements over time in CFRD-associated
mortality: comparison of the periods between 1992 and1997 and
2003–2008 (that interestingly correspond to the periods of obser-
vation of the Liou population and of the Italian population consid-
ered in the present study) revealed that among CF patients with
CFRD female mortality dropped from 6.9 to 3.2 deaths per 100
patient-years, and male mortality dropped from 6.5 to 3.8 deaths
per 100 patient-years (29). Similarly, in 2008, lung function was
still worse in CF patients with CFRD compared to those without
diabetes, but the gap had narrowed and there was no longer a sex
difference in mortality. In agreement with these observations, a
recent report from UK, based on national registry data, estimated
a more modest increase in mortality associated to CFRD as com-
pared to the increase in mortality risk reported by Liou (30). In
our model CFRD was not a significant prognostic factor. Overall
these data suggest that early identification and treatment of
CFRD recommended over the last decade might have reducedits negative impact on survival through better glycemic control
(30).
In this study we also developed a new predictive survival
model based on the Italian cohort data. Similar to the Liou
model, FEV1, number of pulmonary exacerbations and fre-
quency of S. aureus and B. cepacia complex infections were
significantly associated with 5-year survivorship, but this was
not the case for age, gender, weight for age z-score, pancreatic
sufficiency, CFRD and the interaction between exacerbation
and B. cepacia complex, that in contrast were all included in
the Liou model.
It should be noted that our population is smaller than that
considered by Liou, therefore the 5 eliminated covariates may
not be truly non-informative, but rather their association with
mortality may have been undetected due to a lower power of
our study. On the other hand, the odds ratio (that may reflect
the actual disease) are not so different between the two studies,
suggesting that the underlying CF disease is relatively the same
between the two eras and locations, even if the patients are better
due to the changes in care since 1993.
The ability of the newly developed “parsimonious model” in
predicting survival was similar to that reported by the “full
model” that included all the variables selected by Liou. In addi-
tion, FEV1 alone was confirmed to have a high diagnostic accura-
cy in predicting mortality. Overall our data on the diagnostic
accuracy agree with those reported by Mayer-Hamblett et al. and
suggest that survival models based on multiple clinical variables
or FEV1 alone are better predictors of survival thanmortality (31).
Pseudomonas aeruginosa is the most common bacterial path-
ogen causing chronic pulmonary infection in CF;mucoidP. aerugi-
nosa is considered to play a major role in lung disease progression
(32) and in limiting survival (33). However,P. aeruginosa infection
was not found to be associated with 5-year survivorship by Liou et
al. in their original study (2) and it was therefore not considered in
the present study. Like Liou, we found that S. aureus infection,
that occursmore frequently in younger CF patients, is apparently as-
sociated with improved survival. This finding may indirectly reflect
the lack of chronic P. aeruginosa infection (34), and this hypothesis
is strengthened by the fact that in Italy anti-staphylococcal prophy-
laxis (which remains controversial for its possible association with
P. aeruginosa infection) is infrequently carried out (35).
In conclusion, to the best of our knowledge this is the first
study that tested the validity of the Liou survival model in patients
outside the US. In our population, this model, a decade after its
validation, could not accurately predict 5-year survival and we
observed a substantial difference between expected and observed
deaths, with a significant reduction in overall mortality.
Differences in clinical and genetic characteristics of the two
patient populations and a birth cohort effect may be responsible
of this observation. Indeed, over the last decade substantial im-
provements in therapeutic approaches and survival have occurred.
We have also developed a simple model to estimate 5-year
survival, based on four easily available clinical characteristics
that may be useful for identification of high-risk patients. Fur-
ther studies should address the validity of the “parsimonious
model” that we have developed in the present study as well as
of other predictive survival models, that may consider other
29R. Buzzetti et al. / Journal of Cystic Fibrosis 11 (2012) 24–29clinical variables (including P. aeruginosa infection), prospec-
tively collected in larger CF patient populations.
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